Inspire Medical Systems, Inc.
Inspire Medical Systems Reports Strong Q3 2025 Financial Results and Updates Outlook
Summary
Inspire Medical Systems, Inc. reported a 10% increase in revenue for Q3 2025, reaching $224.5 million, and increased its full-year diluted net income per share guidance to a range of $0.90 to $1.00. The company also completed a $50 million share repurchase and presented positive safety and efficacy data for its Inspire V system. The Q3 financial results included an increase in gross margin to 85.8% and operating cash flow of $68.5 million, though net income and diluted EPS decreased compared to the prior year.
Profitelligence Alerts
Get alerts for INSP
Be first to know when Inspire Medical Systems, Inc. files with the SEC.
Filing Categories
Advertisement
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc. is a pioneering company focused on developing and commercializing innovative medical technology designed to treat obstructive sleep apnea (OSA). The company's flagship product, the Inspire therapy, is an implantable neurostimulation device that provides a unique and effective solution for patients who are unable to utilize traditional continuous positive airway pressure (CPAP) devices. Inspire Medical Systems significantly impacts the healthcare sector by offering a less invasive, patient-friendly alternative to surgical treatments for OSA, improving quality of life for those affected by sleep disorders. Headquartered in Minnesota, Inspire Medical Systems continues to expand its presence within the medical device market, collaborating closely with hospitals and medical professionals to enhance sleep health management globally. This company's contributions underscore a growing focus on personalized and technologically advanced approaches to medical challenges, marking its importance in the evolving landscape of healthcare solutions.
Official SEC Documents
Advertisement